Patients with systemic lupus erythematosus are deficient in complement-dependent prevention of immune precipitation

Rheumatology

Volumn 43, Issue 6, 2004, Pages 783-789

  Arason, G J ^a   Steinsson, K ^a   Kolka, R ^a   Vikingsdottir Th ^a   D'Ambrogio, M S ^b   Valdimarsson, H ^a  

^a LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^b CALDERDALE ROYAL HOSPITAL   (United Kingdom)

Author keywords

Antigen antibody complex; Autoimmune disease; Autoimmunity; Complement; SLE

Indexed keywords

COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3D; COMPLEMENT COMPONENT C4; COMPLEMENT COMPONENT C4A; COMPLEMENT COMPONENT C4B;

ADULT; AGAR GEL ELECTROPHORESIS; AGED; ALLOTYPE; ANTIGEN ANTIBODY COMPLEX; ARTICLE; BLOOD DONOR; CLINICAL ARTICLE; COMPLEMENT HEMOLYSIS TEST; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE PREDISPOSITION; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOELECTROPHORESIS; MALE; PATHOGENESIS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SENSITIVITY ANALYSIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; AGED; AGED, 80 AND OVER; ANTIGEN-ANTIBODY COMPLEX; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; COMPLEMENT C4A; COMPLEMENT HEMOLYTIC ACTIVITY ASSAY; COMPLEMENT SYSTEM PROTEINS; DISEASE PROGRESSION; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED;

EID: 3042593372     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/keh183     Document Type: Article

References (48)

1. Wallace DH, Hahn BH (eds). Dubois' Lupus erythematosus, 5th edn. Baltimore: Lippincott, Williams & Wilkins, 1997.
2. Lachmann PJ, Walport, MJ. Deficiency of the effector mechanisms of the immune response and autoimmunity. Ciba Found Symp 1987;129:149-71.
3. Walport MJ, Davies KA, Morley BJ, Botto M. Complement deficiency and autoimmunity. Ann NY Acad Sci 1997;815:267-81.
4. Sullivan KE. Complement deficiency and autoimmunity. Curr Opin Pediatr 1998;10:600-6.
5. Schifferli JA, Ng YC, Peters DK. The role of complement and its receptor in the elimination of immune complexes. N Engl J Med 1986;315:488-95.
6. Agnello V. Lupus diseases associated with hereditary and acquired deficiencies of complement. Springer Semin Immunopathol 1986; 9:161-78.
7. Christiansen FT, Zhang WJ, Griffiths M, Mallal SA, Dawkins RL. Major histocompatibility complex (MHC) complement deficiency, ancestral haplotypes and systemic lupus erythematosus (SLE): C4 deficiency explains some but not all of the influence of the MHC. J Rheumatol 1991;18:1350-8.
8. Law SK, Dodds AW, Porter RR. A comparison of the properties of two classes, C4A and C4B, of the human complement component C4. EMBO J 1984;3:1819-23.
9. Kishore N, Shah D, Skanes VM, Levine RP. The fluid-phase binding of human C4 and its genetic variants, C4A3 and C4B1, to immunoglobulins. Mol Immunol 1988;25:811-19.
10. Yamada H, Watanabe A, Mimori A. et al. Lack of gene deletion for complement C4A deficiency in Japanese patients with systemic lupus erythematosus. J Rheumatol 1990;17:1054-7.
11. Hong GH, Kim HY, Takeuchi F. et al. Association of complement C4 and HLA-DR alleles with systemic lupus erythematosus in Koreans. J Rheumatol 1994;21:442-7.
12. Ratnoff WD. Inherited deficiencies of complement in rheumatic diseases. Rheum Dis Clin N Am 1996;22:75-94.
13. Schur PH. Complement and systemic lupus erythematosus. In: Wallace DH, Hahn BH (eds). Dubois' Lupus erythematosus. Baltimore: Lippincott, Williams & Wilkins, 1997:245-61.
14. Steinsson K, Jonsdottir S, Arason GJ, Fossdal R, Skaftadottir I, Arnason A. A study of the association of HLA DR, DQ, and complement C4 alleles with systemic lupus erythematosus in Iceland. Ann Rheum Dis 1998;57:503-5.
15. Sullivan KE, Kim NA, Goldman D, Petri MA. C4 deficiency due to a 2 bp insertion is increased in patients with systemic lupus erythematosus. J Rheumatol 1999;26:2144-7.
16. Schur PH, Marcus-Bagley D, Awdeh Z, Yunis EJ, Alper CA. The effect of ethnicity on major histocompatibility complex complement allotypes and extended haplotypes in patients with systemic lupus erythematosus. Arthritis Rheum 1990;33:985-92.
17. Hartung K, Baur MP, Codewey R. et al. Major histocompatibility complex haplotypes and complement C4 alleles in systemic lupus erythematosus. Results of a multicenter study. J Clin Invest 1992; 90:1346-51.
18. Hammond A, Ollier W, Walport MJ. Effects of C4 null alleles and homoduplications on quantitative expression of C4A and C4B. Clin Exp Immunol 1992;88:163-8.
19. Moulds JM, Warner NB, Arnett FC. Complement component C4A and C4B levels in systemic lupus erythematosus: quantitation in relation to C4 null status and disease activity. J Rheumatol 1993;20:443-7.
20. Reilly BD. Analysis of human C4A and C4B binding to an immune complex in serum. Clin Exp Immunol 1999;117:12-18.
21. Schifferli JA, Steiger G, Paccaud JP, Sjoholm AG, Hauptmann G. Difference in the biological properties of the two forms of the fourth component of human complement (C4). Clin Exp Immunol 1986;63:473-7.
22. Arason GJ, D'Ambrogio MS, Vikingsdottir T, Sigfusson A, Valdimarsson H. Enzyme immunoassays for measuring complement-dependent prevention of immune precipitation (PIP) and solubilization of preformed antigen-antibody complexes (SOL). J Immunol Methods 1999;223:37-46.
23. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum 1992;35:630-40.
24. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
25. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
26. Schneider PM, Rittner C. Complement genetics. In: Dodds AW, Sim RB (eds). Complement, a practical approach. Oxford: Oxford University Press, 1997:165-99.
27. Roos MH, Mollenhauer E, Demant P, Rittner CA. A molecular basis for the two locus model of human complement component C4. Nature 1982;298:854-6.
28. Mauff G, Steuer M, Week M, Bender K. The C4 beta-chain: evidence for a genetically determined polymorphism. Hum Genet 1983: 64:186-8.
29. Rebmann V, Doxiadis I, Kubens BS, Grosse-Wilde H. Quantitation of the human component C4: definition of C4 Q0 alleles and C4A duplications. Vox Sang 1992;62:117-23.
30. Mollnes TE. Quantification of the C3d split products of human complement by a sensitive enzyme-linked immunosorbent assay. Scand J Immunol 1985;21:607-13
31. Traustadottir KH, Rafnar BO, Steinsson K, Valdimarsson H, Erlendsson K. Participation of factor B in residual immune complex red cell binding activity observed in serum from a C2-deficient systemic lupus erythematosus patient may delay the appearance of clinical symptoms. Arthritis Rheum 1998;41:427-34.
32. Senaldi G, Makinde VA, Vergani D, Isenberg DA. Correlation of the activation of the fourth component of complement (C4) with disease activity in systemic lupus erythematosus. Ann Rheum Dis 1988; 47:913-17.
33. Röther E, Lang B, Coldewey R, Hartung K, Peter HH. Complement split product C3d as an indicator of disease activity in systemic lupus erythematosus. Clin Rheumatol 1993;12:31-5.
34. Traustadottir KH, Steinsson K, Erlendsson K. C4AQ0 superimposed on a primary defect increases the susceptibility to systemic lupus erythematosus (SLE) in a family with association between C4AQ0 and SLE. J Rheumatol 1998;25:2118-25.
35. Wisnieski JJ, Nathanson MH, Anderson JE, Davis AE, 3rd, Alper CA, Naff GB. Metabolism of C4 and linkage analysis in a kindred with hereditary incomplete C4 deficiency. Arthritis Rheum 1987; 30:919-27.
36. Mayumi M, Heike T, Mikawa H. Transient selective C4 deficiency of infancy. Lancet 1992;339:752.
37. Truedsson L, Awdeh Z, Yunis EJ, Mrose S, Moore B, Alper CA. Quantitative variation of C4 variant proteins associated with many MHC haplotypes. Immunogenetics 1989;30:414-21.
38. Porter RR. Complement polymorphism, the major histocompatibility complex and associated diseases: a speculation. Mol Biol Med 1983;1:161-8.
39. Hory B, Haultier JJ. Glomerulonephritis and hereditary angioedema: report of 2 cases. Clin Nephrol 1989;31:259-63.
40. Walport MJ, Davies KA, Botto M. et al. C3 nephritic factor and SLE: report of four cases and review of the literature. Q J Med 1994;87:609-15.
41. Tan EM. Pathophysiology of antinuclear antibodies in systemic lupus erythematosus and related diseases. Adv Dent Res 1996;10:44-6.
42. Casciola-Rosen L, Rosen A. Ultraviolet light-induced keratinocyte apoptosis: a potential mechanism for the induction of skin lesions and autoantibody production in LE. Lupus 1997;6:175-80.
43. Speirs C, Fielder AH, Chapel H, Davey NJ, Batchelor JR. Complement system protein C4 and susceptibility to hydralazine-induced systemic lupus erythematosus. Lancet 1989;1:922-4.
44. Mitchell JA, Batchelor JR, Chapel H, Spiers CN, Sim E. Erythrocyte complement receptor type 1 (CR1) expression and circulating immune complex (CIC) levels in hydralazine-induced SLE. Clin Exp Immunol 1987;68:446-56.
45. Sim E, Gill EW, Sim RB. Drugs that induce systemic lupus erythematosus inhibit complement component C4. Lancet 1984; 2:422-4.
46. Sim E. Law SK. Hydralazine binds covalently to complement component C4. Different reactivity of C4A and C4B gene products. FEBS Lett 1985;84:323-7.
47. Sim E, Dodds AW, Goldin A. Inhibition of the covalent binding reaction of complement component C4 by penicillamine, an anti-rheumatic agent. Biochem J 1989;259:415-19.
48. Sim E, Stanley L, Gill EW, Jones A. Metabolites of procainamide and practolol inhibit complement components C3 and C4. Biochem J 1988;251:32.